

1199 SEIU Benefit Funds
Medical Drug Management Code List

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact 1199 SEIU Benefit Funds or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Abatacept	Orencia	Agents	J0129	N	N	Y: PA Required		Y
Abilify maintena	Aripiprazole	Agents	J0401	N	N	Y: NO PA Required	Mental Health Parity	Y
AbobotulinumtoxinA	Dysport	Neuromusclar Drugs	J0586	N	N	Y: PA Required		Y
Adalimumab	Humira	Inflammatory Conditions	J0139	N	N	Y: PA Required		Y
Adalimumab-aacf	Idacio	Inflammatory Conditions	Q5144	N	N	Y: PA Required		Y
Adalimumab-aaty	Yuflyma	Inflammatory Conditions	Q5141	N	N	Y: PA Required		Y
Adalimumab-adaz	Hyrimoz	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-adaz	Hyrimoz	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-adaz	Sandoz	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-adaz	Sandoz	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-adbm	Cyltezo	Inflammatory Conditions	Q5143	N	N	Y: PA Required		Y
Adalimumab-afzb	Abrilada	Inflammatory Conditions	Q5145	N	N	Y: PA Required		Y
Adalimumab-aqvh	Yusimry	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-aqvh	Yusimry	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-atto	Amjevita	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-atto	Amjevita	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-bwwd	Hadlima	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-bwwd	Hadlima	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-fkjp	Hulio	Inflammatory Conditions	Q5140	N	N	Y: PA Required		Y
Adalimumab-ryrk	Simlandi	Inflammatory Conditions	Q5142	N	N	Y: PA Required		Y
ADAMTS13, Recombinant-krhn	Adzyna	Congenital thrombotic thrombocytopenic purpura	J7171	N	N	Y: PA Required		Y
Afamelanotide	Scenesse	Topical Products	J7352	N	N	Y: PA Required		Y
Afibercept	Eylea	Throat/Dental/Ophthalmic/O	J0178	N	N	Y: PA Required		Y
Afibercept	Eylea HD	Throat/Dental/Ophthalmic/O	J0177	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Agalsidase Beta	Fabrazyme	Endocrine and Metabolic Drugs	J0180	N	N	Y: PA Required		Y
Alemtuzumab	Lemtrada	Psychotherapeutic and Neurological Agents	J0202	N	N	Y: PA Required		Y
Alglucosidase Alfa	Lumizyme	Endocrine and Metabolic Drugs	J0221	N	N	Y: PA Required		Y
Alpha1-proteinase inhibitors	Aralast NP, Prolastin-C, Zemaira	Respiratory Agents	J0256	N	N	Y: PA Required		Y
Alpha1-proteinase inhibitors	Glassia	Respiratory Agents	J0257	N	N	Y: PA Required		Y
Anifrolumab-fnia	Saphnelo	Miscellaneous Products	J0491	N	N	Y: PA Required		Y
Antihemophilic Factor (Recombinant)	Obizur	Hematological Agents	J7188	N	N	Y: PA Required		Y
Antihemophilic factor (recombinant). glycopegylated-exei	Esperoct	Hematological Agents	J7204	N	N	Y: PA Required		Y
Anti-inhibitor	Feiba	Hematological Agents	J7198	N	N	Y: PA Required		Y
Apomorphine	Apokyn	Neuromuscular Drugs	J0364	N	N	Y: PA Required		Y
Aripiprazole lauroxil	Aristada	Agents	J1944	N	N	Y: NO PA Required	Mental Health Parity	Y
Aripiprazole lauroxil	Aristada Initio	Central Nervous System Agents	J1943	N	N	Y: NO PA Required	Mental Health Parity	Y
Atidarsagene autotemcel	Lenmeldy	Hematological Agents	C9399	N	N	Y: PA Required	Embarc: Inpatient	Y
Atidarsagene autotemcel	Lenmeldy	Hematological Agents	J3590	N	N	Y: PA Required	Embarc: Inpatient	Y
Avacincaptad pegol	Izervay	Ophthalmic Agents	J2782	N	N	Y: PA Required		Y
Avalglucosidase alfa-ngpt	Nexviazyme	Drugs	J0219	N	N	Y: PA Required		Y
Belatacept	Nulojix	Immunosuppressive Agents	J0485	N	N	Y: PA Required		Y
Belimumab	Benlysta	Miscellaneous Products	J0490	N	N	Y: PA Required		Y
Benralizumab	Fasenra	Respiratory Agents	J0517	N	N	Y: PA Required		Y
Beremagene geperpavec-svdt	Vyjuvek	Topical Products	J3401	N	N	Y: PA Required		Y
Betibeglogene autotemcel	Zynteglo	Hematological Agents	J3393	N	N	Y: PA Required	Embarc: Inpatient	Y
Bevacizumab	Avastin	Antineoplastic Agents and Adjunctive Therapies	J7999	N	N	Y: PA Required		Y
Bevacizumab	Avastin	Adjunctive Therapies	C9257	N	N	Y: PA Required		Y
Bezlotoxumab	Zinplava	Biologicals	J0565	N	N	Y: PA Required		Y
Bimatoprost Intracameral implant	Durysta	Ophthalmic Agents	J7351	N	N	Y: PA Required		Y
Brolucizumab-dbil	Beovu	Ophthalmic Agents	J0179	N	N	Y: PA Required		Y
Burosumab-twza	Crysvita	Drugs	J0584	Y	N	Y: PA Required		Y
C1 Esterase Inhibitor	Berinert	Hematological Agents	J0597	N	N	Y: PA Required		Y
C1 Esterase Inhibitor	Cinryze	Hematological Agents	J0598	N	N	Y: PA Required		Y
C1 Esterase Inhibitor	Ruconest	Hematological Agents	J0596	N	N	Y: PA Required		Y
Cabotegravir and Rilpivirine	Cabenuva	Anti-Infective Agents	J0741	N	N	Y: PA Required		Y
Cabotegravir extended-release injectable suspension	Apretude	Anti-Infective Agents	J0739	N	N	Y: PA Required		Y
Canakinumab	Ilaris	Anti-Inflammatory Agents	J0638	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Eculizumab-aeeb	Bkerv	Hematological Agents	Q5139	N	N	Y: PA Required		Y
Edaravone	Radicava	Neuromusclar Drugs	J1301	N	N	Y: PA Required		Y
Efgartigimod alfa-fcab	Vyvgart	Miscellaneous Products	J9332	N	N	Y: PA Required		Y
Hyaluronidase-qvfc	Vyvgart Hytrulo	Miscellaneous Products	J9334	N	N	Y: PA Required		Y
Elapegademase-lvlr	Revcovi	ADA-SCID	C9399	N	N	Y: PA Required		Y
Elapegademase-lvlr	Revcovi	ADA-SCID	J3590	N	N	Y: PA Required		Y
Elivaldogene autotemcel	Skysona	Hematological Agents	C9399	N	N	Y: PA Required	Embarc: Inpatient	Y
Elivaldogene autotemcel	Skysona	Hematological Agents	J3590	N	N	Y: PA Required	Embarc: Inpatient	Y
Elosulfase Alfa	Vimizim	Drugs	J1322	N	N	Y: PA Required		Y
Emicizumab-kxwh	Hemlibra	Hematological Agents	J7170	N	N	Y: PA Required		Y
Epoetin Alfa	Epogen, Procrit	Hematological Agents	J0885	Y	N	Y: PA Required		Y
Epoetin alfa - epbx	Retacrit	Hematological Agents	Q5106	Y	N	Y: PA Required		Y
Epoprostenol	Epoprostenol, Flolan, Veletri	Cardiovascular Agents	J1325	N	N	Y: PA Required		Y
Eptinezumab-jjmr	Vyepti	Analgesics and Anesthetics	J3032	N	N	Y: PA Required		Y
Esketamine	Spravato	Central Nervous Systems Drugs	S0013	N	N	Y: PA Required	Mental Health Parity	Y
Etanercept	Enbrel	Inflammatory Conditions	J1438	N	N	Y: PA Required		Y
Eteplirsen	Exondys 51	Neuromusclar Drugs	J1428	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Etranacogene Dezaparovec-drlb	Hemgenix	Hematological Agents	J1411	N	N	Y: PA Required	Embarc Outpatient	Y
Evinacumab-dgnb	Evkeeza	Cardiovascular Agents	J1305	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Evolocumab	Repatha	Lipid Disorders	C9399	N	N	Y: PA Required		Y
Evolocumab	Repatha	Lipid Disorders	J3590	N	N	Y: PA Required		Y
Exagamglogene autotemcel	Casgevy	Hematological Agents	J3392	N	N	Y: PA Required	Embarc: Inpatient	Y
recombinant)	Idelvion	Hematological Agents	J7202	N	N	Y: PA Required		Y
purified, non-recombinant)	AlphaNine SD, Mononine	Hematological Agents	J7193	N	N	Y: PA Required		Y
recombinant)	BeneFix	Hematological Agents	J7195	N	N	Y: PA Required		Y
recombinant)	Ixinity	Hematological Agents	J7213	N	N	Y: PA Required		Y
recombinant)	Rixubis	Hematological Agents	J7200	N	N	Y: PA Required		Y
recombinant), glycopegylated	Rebinyon	Hematological Agents	J7203	N	N	Y: PA Required		Y
recombinant)	Alprolix	Hematological Agents	J7201	N	N	Y: PA Required		Y
Factor IX Complex	Bebulin, Proflinine/Proflinine SD	Hematological Agents	J7194	N	N	Y: PA Required		Y
Factor viia (antihemophilic factor, recombinant)-jncw	Sevenfact	Hematological Agents	J7212	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Factor VIII (antihemophilic factor, human)	Koate/Koate-DVI, Hemofil M	Hematological Agents	J7190	N	N	Y: PA Required		Y
recombinant)	Afstyla	Hematological Agents	J7210	N	N	Y: PA Required		Y
recombinant)	Kovaltry	Hematological Agents	J7211	N	N	Y: PA Required		Y
recombinant)	Nuwiq	Hematological Agents	J7209	N	N	Y: PA Required		Y
recombinant), pegylated	Adynovate	Hematological Agents	J7207	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, recombinant), pegylated-aucl	Jivi	Hematological Agents	J7208	N	N	Y: PA Required		Y
Factor VIII (antihemophilic Factor,Recombinant)	Advate, Kogenate FS, Recombinate	Hematological Agents	J7192	N	N	Y: PA Required		Y
Factor,Recombinant)	Novoeight	Hematological Agents	J7182	N	N	Y: PA Required		Y
Factor,Recombinant)	Xyntha	Hematological Agents	J7185	N	N	Y: PA Required		Y
Factor VIII (Fc fusion protein, recombinant)	Eloctate	Hematological Agents	J7205	N	N	Y: PA Required		Y
Complex, Recombinant	Altuviiio per factor viii iu	Hematological Agents	J7214	N	N	Y: PA Required		Y
Factor XIII Concentrate (antihemophilic factor, human)	Corifact	Hematological Agents	J7180	N	N	Y: PA Required		Y
recombinant)	NovoSeven-RT	Hematological Agents	J7189	N	N	Y: PA Required		Y
Faricimab-svoa	Vabysmo	Ophthalmic Conditions	J2777	N	N	Y: PA Required		Y
Fecal Microbiota, Live-jsl	Rebyota	Gastrointestinal Agents	J1440	N	N	Y: PA Required		Y
Ferric Carboxymaltose	Injectafer	Hematological Agents	J1439	N	N	Y: PA Required		Y
Ferric Derisomaltose	Monoferic	Hematological Agents	J1437	N	N	Y: PA Required		Y
Ferumoxylol	Feraheme	Hematological Agents	Q0138	N	N	Y: PA Required		Y
Fibrinogen (Human)	RiaSTAP	Hematological Agents	J7178	Y	N	Y: PA Required		Y
Fidanacogene elaparovvec-dzkt	Beqvez	Gene Therapy for the Treatment of Hemophilia B	J1414	N	N	Y: PA Required	Embarc: Outpatient	Y
Filgrastim	Neupogen	Hematological Agents	J1442	Y	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Filgrastim-aafi	Nivestym	Hematological Agents	Q5110	Y	N	Y: PA Required		Y
Filgrastim-ayow	Releuko	Hematological Agents	Q5125	Y	N	Y: PA Required		Y
Filgrastim-sndz	Zarxio	Hematological Agents	Q5101	Y	N	Y: PA Required		Y
Filgrastim-txid	Nypozi	Hematological Agents	J3590	Y	N	Y: PA Required		Y
Filgrastim-txid	Nypozi	Hematological Agents	C9173	Y	N	Y: PA Required		Y
Fosdenopterin	Nulibry	Deficiency	C9399	N	N	Y: PA Required		Y
Fosdenopterin	Nulibry	Deficiency	J3490	N	N	Y: PA Required		Y
Galsulfase	Naglazyme	Endocrine and Metabolic Drugs	J1458	N	N	Y: PA Required		Y
Givosiran	Givlaari	Hematological Agents	J0223	N	N	Y: PA Required		Y
Golimumab	Simponi Aria	Analgesics and Anesthetics	J1602	N	N	Y: PA Required		Y
Golodirsen	Vyondys 53	Neuromusclar Drugs	J1429	N	N	Y: PA Required		Y
Guselkumab, Intravenous Injection	Tremfya	Ulcerative Colitis	J1628	N	N	Y: PA Required		Y
Histrelin Acetate	Supprelin LA	Endocrine and Metabolic Drugs	J9226	N	N	Y: PA Required		Y
Human fibrinogen concentrate	Fibryga	Hematological Agents	J7177	N	N	Y: PA Required		Y
Ibalizumab-uryk	Trogarzo	Anti-Infective Agents	J1746	N	N	Y: PA Required		Y
Idursulfase	Elaprase	Drugs	J1743	N	N	Y: PA Required		Y
Imiglucerase	Cerezyme	Hematological Agents	J1786	N	N	Y: PA Required		Y
Immune Globulin	Bivigam	Biologicals	J1556	N	N	Y: PA Required		Y
Immune Globulin	Carimune NF, Gammagard S/D, Panglobulin NF	Biologicals	J1566	N	N	Y: PA Required		Y
Immune Globulin	Cuvitru	Biologicals	J1555	N	N	Y: PA Required		Y
Immune Globulin	Gammaked, Gamunex-C, Hizentra, Xembify	Biologicals	90284	N	N	Y: PA Required		Y
Immune Globulin	Flebogamma DIF	Biologicals	J1572	N	N	Y: PA Required		Y
Immune Globulin	Gammagard liquid	Biologicals	J1569	N	N	Y: PA Required		Y
Immune Globulin	Bivigam, Flebogamma,	Biologicals	90283	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Injection, romosozumab-aqgg, 1 mg	Evenity	Endocrine and Metabolic Drugs	J3111	N	N	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Durolane	Neuromusclar Drugs	J7318	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Euflexxa	Neuromusclar Drugs	J7323	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Gel-One	Neuromusclar Drugs	J7326	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Gelsyn-3	Neuromusclar Drugs	J7328	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Genvisc 850	Neuromusclar Drugs	J7320	N	Preferred - Orthovisc Preferred - Monovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	(Visco-3 as of 4/1/21)	Neuromusclar Drugs	J7321	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Hymovis	Neuromusclar Drugs	J7322	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Monovisc	Neuromusclar Drugs	J7327	N	Preferred - Orthovisc Preferred - Monovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Orthovisc	Neuromusclar Drugs	J7324	N	Preferred - Orthovisc	Y: PA Required		Y
					Preferred - Orthovisc Preferred - Monovisc Non-Preferred - Durolane Non-Preferred - Gel-One Non-Preferred - Gelsyn-3 Non-Preferred - GenVisc 850			
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	Neuromusclar Drugs	C9399	N		Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	Neuromusclar Drugs	J3490	N	Preferred - Orthovisc	Y: PA Required		Y
					Preferred - Orthovisc Preferred - Monovisc Non-Preferred - Durolane Non-Preferred - Gel-One Non-Preferred - Gelsyn-3 Non-Preferred - GenVisc 850			
Intra-Articular Hyaluronan Injections	Synjoynt	Neuromusclar Drugs	J7331	N		Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Synvisc, Synvisc-One	Neuromusclar Drugs	J7325	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Triluron	Neuromusclar Drugs	J7332	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	TriVisc	Neuromusclar Drugs	J7329	N	Preferred - Orthovisc	Y: PA Required		Y
Lanreotide	Somatuline	Drugs	J1930	Y	N	Y: PA Required		Y
Lanreotide (Cipla)	Lanreotide (Cipla)	Drugs	J1932	Y	N	Y: PA Required		Y
Laronidase	Aldurazyme	Endocrine and Metabolic Drugs	J1931	N	N	Y: PA Required		Y
Lecanemab-irnb	Leqembi	Neurological Agents -	J0174	N	N	Y: PA Required		Y
Lenacapavir	Sunlenca	Anti-Infective Agents	J1961	N	N	Y: PA Required		Y
Leuprolide acetate	Fensolvi	Endocrine and Metabolic Drugs	J1951	N	N	Y: PA Required		Y
Leuprolide acetate	Lupron	Endocrine and Metabolic Drugs	J1950	Y	N	Y: PA Required		Y
Liraglutide	Saxenda	GLP-1 Agonist Drug Class	J3490	N	N	Y: PA Required		Y
Lovotibeglogene autotemcel	Lyfgenia	Hematological Agents	J3394	N	N	Y: PA Required	Embarc: Inpatient	Y
Lumasiran	Oxlumo	Genitourinary Products	J0224	N	N	Y: PA Required		Y
Luspatercept-aamt	Reblozyl	Hematological Agents	J0896	Y	N	Y: PA Required		Y
Mepolizumab	Nucala	Respiratory Agents	J2182	N	N	Y: PA Required		Y
Methoxy Polyethylene Glycol-Epoetin Beta	Mircera, Mircera for NON-ESRD	Hematological Agents	J0888	N	N	Y: PA Required		Y
Mirikizumab-mrkz	Omvoh	Colitis	J2267	N	N	Y: PA Required		Y
Natalizumab	Tysabri	Neurological Agents -	J2323	N	N	Y: PA Required		Y
Nusinersen	Spinraza	Neuromusclar Drugs	J2326	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Pegcetaplan	Syfovre	Ophthalmic Conditions	J2781	N	N	Y: PA Required		Y
Pegloticase	Krystexxa	Analgesics and Anesthetics	J2507	N	N	Y: PA Required		Y
Pegunigalsidase alfa-iwxj	Elfabrio	Drugs	J2508	N	N	Y: PA Required		Y
Pimavanserin	Nuplazid	Central Nervous System Agents	J8499	N	N	Y: NO PA Required	Mental Health Parity	Y
Plasminogen, human-tvmh	Ryplazim	Hematological Agents	J2998	N	N	Y: PA Required		Y
Pozelimab-bbfg	Veopoz	Hematological Agents	J9376	N	N	Y: PA Required		Y
Ranibizumab	Lucentis	Ophthalmic Conditions	J2778	N	N	Y: PA Required		Y
Ranibizumab	Susvimo	Ophthalmic Conditions	J2779	N	N	Y: PA Required		Y
Ranibizumab-eqrm	Cimerli	Ophthalmic Conditions	Q5128	N	N	Y: PA Required		Y
Ranibizumab-nuna	Byooviz	Ophthalmic Conditions	Q5124	N	N	Y: PA Required		Y
Ravulizumab-cvvz	Ultomiris	Hematological Agents	J1303	N	N	Y: PA Required		Y
Remdesivir	Veklury	Anti-Infective Agents	J0248	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Reslizumab	Cinqair	Respiratory Agents	J2786	N	N	Y: PA Required		Y
Rilonacept	Arcalyst	Analgesics and Anesthetics	J2793	N	N	Y: PA Required		Y
RimabotulinumtoxinB	Myobloc	Neuromusclar Drugs	J0587	N	N	Y: PA Required		Y
Risankizumab-rzaa	Skyrizi	Gastrointestinal Agents	J2327	N	N	Y: PA Required		Y
Rituximab	Rituxan	Antineoplastic Agents and Adjunctive Therapies	J9312	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y
Rituximab-abbs	Truxima	Antineoplastic Agents and Adjunctive Therapies	Q5115	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y
Rituximab-arrx	Riabni	Antineoplastic Agents and Adjunctive Therapies	Q5123	Y	Preferred - Riabni Preferred - Ruxience Preferred - Truxima Non-Preferred - Rituxan	Y: PA Required		Y
Rituximab-pvvr	Ruxience	Antineoplastic Agents and Adjunctive Therapies	Q5119	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Romiplostim	Nplate	Hematological Agents	J2802	Y	N	Y: PA Required		Y
Rozanolixizumab-noli	Rystiggo	Miscellaneous Products	J9333	N	N	Y: PA Required		Y
Sebelipase alfa	Kanuma	Endocrine and Metabolic Drugs	J2840	N	N	Y: PA Required		Y
Secukinumab	Cosentyx	Arthritis, Ankylosing	J3247	N	N	Y: PA Required		Y
Spesolimab-sbzo	Spevigo	Dermatologic Agents	J1747	N	N	Y: PA Required		Y
Sutimlimab-jome	Enjaymo	Hematological Agents	J1302	N	N	Y: PA Required		Y
Taliglucerase Alfa	Elelyso	Drugs	J3060	N	N	Y: PA Required		Y
Teplizumab-mzvw	Tzield	Drugs	J9381	N	N	Y: PA Required		Y
Teprotumumab-trbw	Tepezza	Drugs	J3241	N	N	Y: PA Required		Y
Tezepelumab-ekko	Tezspire	Respiratory Agents	J2356	N	N	Y: PA Required		Y
Tildrakizumab-asmn	Ilumya	Topical Products	J3245	N	N	Y: PA Required		Y
Tocilizumab	Actemra	Anti-Inflammatory Agents	J3262	Y	N	Y: PA Required		Y
Tocilizumab-aazg	Tyenne	Anti-Inflammatory Agents	Q5135	Y	N	Y: PA Required		Y
Tocilizumab-bavi	Tofidence	Anti-Inflammatory Agents	Q5133	Y	N	Y: PA Required		Y
Tofersen	Qalsody	Neuromusclar Drugs	J1304	N	N	Y: PA Required		Y
Travaprost Intracameral Implant	iDose TR	glaucoma (OAG) or ocular hypertension (OHT)	J7355	N	N	Y: PA Required		Y
Treprostinil	Remodulin	Cardiovascular Agents	J3285	N	N	Y: PA Required		Y
Triamcinolone ER	Zilretta	Agents	J3304	N	N	Y: PA Required		Y
Triptorelin ER	Triptodur	Drugs	J3316	N	N	Y: PA Required		Y
Ublituximab-xiyi	Briumvi	Neurological Agents - Miscellaneous	J2329	N	N	Y: PA Required		Y
Ustekinumab	Stelara	Chrohn's disease & Ulcerative Colitis	J3358	N	N	Y: PA Required		Y
Ustekinumab	Stelara	Chrohn's disease & Ulcerative Colitis	J3357	N	N	Y: PA Required		Y
Ustekinumab-auub	Wezlana	Chrohn's disease & Ulcerative Colitis	Q5137	N	N	Y: PA Required		Y
Ustekinumab-auub	Wezlana	Chrohn's disease & Ulcerative Colitis	Q5138	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Ustekinumab-twe	Pyzchiva	Topical Products	Q9997	N	N	Y: PA Required		Y
Ustekinumab-twe	Pyzchiva	Topical Products	Q9996	N	N	Y: PA Required		Y
Valoctocogene Roxaparvovec-rvox	Roctavian	Hematological Agents	J1412	N	N	Y: PA Required	Embarc: Outpatient	Y
Vedolizumab	Entyvio	Gastrointestinal Agents	J3380	N	N	Y: PA Required		Y
Velaglucerase Alfa	Vpriv	Hematological Agents	J3385	N	N	Y: PA Required		Y
Velmanase alfa-tycv	Lamzede	Endocrine and Metabolic Drugs	J0217	N	N	Y: PA Required		Y
Vestronidase alfa-vjvk	Mepsevii	Endocrine and Metabolic Drugs	J3397	N	N	Y: PA Required		Y
Viltolarsen	Viltepso	Neuromusclar Drugs	J1427	N	N	Y: PA Required		Y
von Willebrand Factor (Recombinant)	Vonvendi	Hematological Agents	J7179	N	N	Y: PA Required		Y
von Willebrand Factor complex	Humate-P	Hematological Agents	J7187	N	N	Y: PA Required		Y
(human)	Alphanate	Hematological Agents	J7186	N	N	Y: PA Required		Y
von Willebrand Factor complex (human)	Wilate	Hematological Agents	J7183	N	N	Y: PA Required		Y
Voretigene Neparvovec-rzyl	Luxturna	outh-	J3398	N	N	Y: PA Required	Embarc: Outpatient	Y
Vutrusiran	Amvuttra	Neurological Agents -	J0225	N	N	Y: PA Required		Y
Zoledronic Acid	Reclast	Drugs	J3489	N	N	Y: PA Required		Y